What Has Been The Historical And Current Growth Of The Postmenopausal Osteoporosis Treatment Market?
The postmenopausal osteoporosis treatment market has seen considerable growth due to a variety of factors.
•The market size of treatment for postmenopausal osteoporosis has seen consistent growth in the past few years. There is an expected rise from $10.1 billion in 2024 to about $10.58 billion in 2025, showing a compound annual growth rate (CAGR) of 4.8%.
The growth experienced during the historic period can be associated with the aging population, hormone replacement therapy, increased awareness levels, risk reduction of fractures, and nutritional supplements.
What Is The Forecast For The Postmenopausal Osteoporosis Treatment Market By 2029?
The postmenopausal osteoporosis treatment market is expected to maintain its strong growth trajectory in upcoming years.
• Significant growth is anticipated in the postmenopausal osteoporosis treatment market in the coming years, with its value expected to reach $13.44 billion in 2029 at a 6.2% compound annual growth rate (CAGR).
This prediction for the forecast period is contributed by factors such as the growth of the healthcare infrastructure, increased screening programs, implementation of precision medicine and biosimilars in treating osteoporosis, women's health programs focusing on bone health, incorporation of digital health, and use of regenerative medicine approaches. Additionally, the forecast period will see major trends such as advances in diagnostics, development of new drugs, emerging therapies, collaborations aimed at drug development, and artificial intelligence integration.
Which Key Drivers Are Propelling The Postmenopausal Osteoporosis Treatment Market's Growth?
The postmenopausal osteoporosis treatment market is anticipated to advance due to the escalating incidence of osteoporosis. Characterized by a reduction in bone mass and a degradation of bone tissue, osteoporosis heightens vulnerability and fracture risk. Treatment of postmenopausal osteoporosis is essential in helping prevent or control the illness, mitigating fracture probability, and importantly, enhancing both the quality of life and health results for those affected. For example, Healthy Bones Australia, a non-governmental organization based in Australia, reported in September 2022 that the number of fractures resulting from osteoporosis or osteopenia had risen from 178,439 in 2021 to 183,105 in 2022. Consequently, the rising incidence of osteoporosis is spurring the progression of the postmenopausal osteoporosis treatment market.
What Are The Key Segments Within The Global Postmenopausal Osteoporosis Treatment Market?
The postmenopausal osteoporosis treatment market covered in this report is segmented –
1) By Drug Type: Bisphosphonates, Vitamin D3, Estrogen Agonist Or Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Other Drug Types
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Bisphosphonates: Alendronate, Risedronate, Zoledronic Acid
2) By Vitamin D3: Cholecalciferol, Ergocalciferol
3) By Estrogen Agonist Or Antagonist: Selective Estrogen Receptor Modulators (SERMs), Tamoxifen
4) By Hormone Replacement Therapy: Estrogen Therapy, Combined Estrogen-Progestin Therapy
5) By Parathyroid Hormone Therapy: Teriparatide, Abaloparatide
6) By Other Drug Types: Calcitonin, RANK Ligand Inhibitors
Pre-Book The Postmenopausal Osteoporosis Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Postmenopausal Osteoporosis Treatment Market?
A predominant trend in the postmenopausal osteoporosis treatment market is the emphasis on product innovations. Leading companies in this domain are striving to create innovative products, such as parathyroid hormone, to enhance efficacy and patient compliance. They are delving into blended treatments and personalized medical approaches to augment outcomes. Moreover, there is a strong focus on conducting comprehensive safety research plans for future treatments and implementing programs that support patients to alleviate their concerns and motivate adherence. Parathyroid hormone (PTH) regulates the blood's calcium levels, stimulates the release of calcium from the bones, increases the kidneys' calcium reabsorption, and induces activation of vitamin D, which augments calcium's absorption in the intestines. For instance, in November 2023, Apotex Corp, a pharmaceutical corporation based in Canada, introduced teriparatide, a bioengineered parathyroid hormone. This product significantly boosts bone mineral density and curbs the risk of fractures in osteoporosis patients. Its anabolic properties promote bone formation, marking it an essential treatment for patients with high fracture risk.
Who Are the Key Players in the Postmenopausal Osteoporosis Treatment Market?
Major companies operating in the postmenopausal osteoporosis treatment market include:
• Pfizer Inc.
• Johnson and Johnson
• F. Hoffmann-La Roche AG
• Merck and Co. Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi SA
• Eli Lilly and Company
• Amgen Inc.
• Asahi Kasei Corporation
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sandoz International GmbH
• Fresenius Kabi AG
• Daiichi Sankyo Company Ltd.
• Sun Pharmaceutical Industries Ltd.
• Cipla Inc.
• Dr.Reddys Laboratories Ltd.
• Hikma Pharmaceuticals PLC.
• Amneal Pharmaceuticals LLC
• Zydus Lifesciences Ltd.
• Takeda Pharmaceutical Company Limited
• Lupin Limited
• Ligand Pharmaceuticals Incorporated
• Torrent Pharmaceuticals Limited.
What are the Regional Insights into the Postmenopausal Osteoporosis Treatment Market?
North America was the largest region in the postmenopausal osteoporosis treatment market in 2024. The regions covered in the postmenopausal osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
